Targeted Therapies for EGFR in Non-small Cell Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 88
Special Issue Editor
Interests: lung cancer; immunotherapy; immune checkpoint inhibitors (ICIs); target therapy; tyrosine kinase inhibitors (TKIs); cancer biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are delighted to announce the call for submissions to a Special Issue of Cancers focusing on the topic of "Targeted Therapies for EGFR in Non-Small Cell Lung Cancer." Non-small cell lung cancer (NSCLC) is a complex disease with various subtypes, and one of the key molecular alterations found in NSCLC is mutations in the epidermal growth factor receptor (EGFR) gene. Targeted therapies directed toward EGFR have revolutionized the treatment landscape for NSCLC patients with EGFR mutations.
This Special Issue aims to provide a comprehensive overview of the current knowledge and advancements in targeted therapies for EGFR mutations in NSCLC, with a focus on personalized treatment approaches. We invite the submissions of original research articles, reviews, and clinical studies that cover various aspects of targeted therapies for EGFR in NSCLC, including but not limited to the following:
- Molecular mechanisms and signaling pathways of EGFR in NSCLC.
- Identification and characterization of EGFR mutations in NSCLC.
- Development of EGFR-targeted therapies, including small molecule inhibitors and monoclonal antibodies.
- Resistance mechanisms to EGFR-targeted therapies and strategies to overcome them.
- Clinical trials and real-world evidence of the efficacy and safety of EGFR-targeted therapies.
We encourage contributions from researchers, clinicians, and experts in the field of lung cancer research and oncology. All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to the field.
By consolidating the latest research findings and clinical trials, we aim to enhance our understanding of EGFR-targeted therapies in NSCLC and drive the development of more effective and personalized treatment strategies. Your valuable contributions will significantly impact the success of this Special Issue.
If you have any questions, require further information, or need any assistance, please do not hesitate to reach out to us. We are here to support and facilitate your participation in this Special Issue.
Thank you for your significant work in this field, and we are looking forward to receiving your valuable submissions.
Dr. Federico Pio Fabrizio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- EGFR
- non-small cell lung cancer
- molecular mechanisms
- targeted therapies
- resistance mechanisms
